openPR Logo
Press release

Global Thalassemia Market 2020 Global Share, Trend, Segmentation And Forecast To 2026|Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio

07-30-2020 05:17 PM CET | Health & Medicine

Press release from: Data Bridge Market Research

Global Thalassemia Market

Global Thalassemia Market

Global Thalassemia Market is expected to rise from its initial estimated value of USD 1.99 billion to a projected value of USD 4.36 billion by 2026, registering a CAGR of 10.29% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing concern and awareness regarding the disease globally.

The Thalassemia business report comprises of primary, secondary and advanced information about the global market with respect to status, trends, size, share, growth, and segments in the forecasted period of 2020 - 2026. Systemic gathering of company profiles that are driving the market is also performed in this report. This market report also measures the existing development trends and patterns along with distribution and marketing channels. The report exhibits important product developments and tracks recent acquisitions, mergers and research in the ABC industry by the key players. The Thalassemia report puts light on the entire market trends and analyses the effect of buyers, consumers, substitutes, new entrants, competitors, and suppliers on the market.

Get Sample Copy Of This Report + All Related Graphs @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-thalassemia-market

Few of the major competitors currently working in the thalassemia market are ApoPharma Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc.; Acceleron Pharma, Inc.; Incyte Corporation; Kiadis Pharma; Gamida Cell; CELGENE CORPORATION; GlaxoSmithKline plc; Ionis Pharmaceuticals, Inc.; Vifor Pharma; La Jolla Pharmaceutical Company; Lonza and Sangamo Therapeutics.

Key Developments in the Market:

In April 2019, CELGENE CORPORATION and Acceleron Pharma, Inc. announced that CELGENE had submitted a Biologics License Application (BLA) for “luspatercept” with the U.S. F.D.A. (United States Food & Drug Administration). This will help in faster commercialization and development of drugs for patients suffering from blood diseases.
In January 2019, Vifor Pharma announced positive results from their phase-I trial of “VIT-2763” an oral ferroportin inhibitor. The drug being developed for transportation of iron from one cell to another has shown signs in reduction of serum iron in a dose-dependent state.

Segmentation: Global Thalassemia Market

By Thalassemia Type

Alpha Thalassemia
Beta Thalassemia
By Therapeutic Class
Iron Chelating Drugs
Exjade/Jadenu (deferasirox)

By Pipeline

Gene Therapy
LentiGlobin

By End-User

Hospitals
Clinics
Research Institutes
Laboratories

By Geography

North America
South America
Europe
Asia-Pacific
Middle East & Africa

Market Drivers

Increasing prevalence of the disease globally without any viable treatment options available for curing the disease; this factor is expected to drive the market growth
Growth in development of pipeline drugs and development of new therapies because of R&D activities and investments by the various authorities; this factor is expected to drive the market growth

Market Restraint

Lack of viable treatment options commercialized for the treatment of disease/disorder rather than the symptoms associated with the disease; this factor is expected to restrain the market growth
High cost of treatment for the disorder is expected to act as a restraint to the market growth

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-thalassemia-market

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Thalassemia Market 2020 Global Share, Trend, Segmentation And Forecast To 2026|Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio here

News-ID: 2100029 • Views:

More Releases from Data Bridge Market Research

Tomato Ketchup Market Size to Surpass USD 19.61 billion at a CAGR of 6.50% by 2029, Share, Growth, Demand, Global Trends, Challenges and Competitive Outlook
Tomato Ketchup Market Size to Surpass USD 19.61 billion at a CAGR of 6.50% by 20 …
A crucial source of information, the Tomato Ketchup Market Research Report provides approaching and current technological and financial aspects of the industry through 2030. For the benefit of readers and end users, all gathered market data is verified and confirmed by industry professionals. With the help of this reliable marketing report, analyzing the actions of major companies and their impact on sales, import, export, revenue, and CAGR numbers becomes simple. The
Community Acquired Pneumonia Drugs Market is Forecasted to Reach USD 2,475.44 million at a CAGR of 7.70% , Size, Share, Trends, Development Strategies, Competitive Scenario and Segmentation Analysis
Community Acquired Pneumonia Drugs Market is Forecasted to Reach USD 2,475.44 mi …
An all-inclusive Community Acquired Pneumonia Drugs Market survey report makes available the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios. The report also recognizes and analyses the emerging trends along with major drivers, challenges and opportunities in the market. The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in
Free from Certification Market is Forecasted to Surge USD 2.00 billion at a CAGR of 6.50% by 2029, Size, Share, Emerging Trends, Key Growth Drivers, Challenges and Industry Revenue Outlook
Free from Certification Market is Forecasted to Surge USD 2.00 billion at a CAGR …
A dependable Free from Certification Market report gives information about company profile, product specifications, capacity, production value, and market shares for each company for the year 2023 to 2030 under the competitive analysis study. Under market segmentation, research and analysis is done based on several market and industry segments such as application, vertical, deployment model, end user, and geography. The report focuses on many aspects related to Free from Certification Market
Steel Piston Market to Observe Utmost USD 2,997.41 million at a CAGR of 4.10% by 2029, Size, Share, Demand, Key Drivers, Development Trends and Competitive Outlook
Steel Piston Market to Observe Utmost USD 2,997.41 million at a CAGR of 4.10% by …
A winning Steel Piston Market report is an established source of information that presents with a telescopic view of the current market trends, situations, opportunities and status. This report helps clients recognize new opportunities and most important customers for their business growth and increased revenue. Moreover, the trends in consumer and supply chain dynamics are also recognized and then accordingly strategies about marketing, promotion and sales are interpreted for an extreme

All 5 Releases


More Releases for Thalassemia

Thalassemia Market to Witness Growth Acceleration | SG Pharma Pvt. Lmt.
The Thalassemia Market Report is designed to incorporate both qualitative and quantitative aspects of the industry with respect to each region and country involved in the study. Furthermore, It studies the market essential sectors such as top participants, expansion strategies, business models, and other industry features to improve the current strategy of key players. Facts and data are presented in reports using diagrams, graphs, pie charts, and other pictorial representations.
Global Thalassemia Market Size – Forecast to 2026
The findings reviewed by GME stated that the Global Thalassemia Market will expand with a CAGR value of 10.2 percent from 2021 to 2026. Several drivers are likely to accelerate the thalassemia market further, including an increasing occurrence of thalassemia, growing public awareness, expanding expenditure in research & development, and the growing need for improved curative gene therapy. Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and
Thalassemia Treatment Market is driven by increase in number of altered thalasse …
Thalassemia Treatment Market - Snapshot The global thalassemia treatment market is driven by increase in number of altered thalassemia genes across the globe. The global market was valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026 to reach US$ 1,639.6 Mn by 2026. The global market is witnessing high growth owing to increase in blood transfusion and chelation therapy
Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” report studies Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin.
Thalassemia - Pipeline Review, H2 2017
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow
Thalassemia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Thalassemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms